reports
Calavo Growers, Inc. Announces $25 Million Stock Repurchase Program
Calavo Growers, Inc. Announces $25 Million Stock Repurchase Program Strong Balance Sheet and Robust Liquidity Position Company for Buybacks to Enhance Shareholder Value SANTA PAULA, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global leader in the avocado industry and provider of value-added fresh food (the “Company” or “Calavo”), today announced that its Board of Directors has authorized a share repurchase program of up to $25 million of the Company's outstanding common stock. “This repurchase program underscores our confidence in our long-t...
Calavo Growers, Inc. Announces First Quarter 2025 Financial Results
Calavo Growers, Inc. Announces First Quarter 2025 Financial Results SANTA PAULA, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global avocado industry leader and provider of value-added fresh food, today reported its financial results for the fiscal first quarter ended January 31, 2025. First Quarter Financial Overview Total net sales of $154.4 million, a 21.0% increase from the prior year quarter. Fresh1 segment sales increased $26.8 million, or 23.7%, from the prior year quarter.Prepared segment sales remained essentially flat from the prior year quarter. ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in conn...
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Pro...
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update...
Calavo Growers to Report First Quarter 2025 Financial Results
Calavo Growers to Report First Quarter 2025 Financial Results SANTA PAULA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in the processing and distribution of avocados, tomatoes, papayas, and guacamole, today announced that it plans to release financial results for the fiscal first quarter ended January 31, 2025, after the market closes on Wednesday, March 12, 2025. About Calavo Growers, Inc.Calavo Growers, Inc. (Nasdaq: CVGW) is a global leader in the processing and distribution of avocados, tomatoes, papayas and guacamole. Calavo products are marketed ...
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and ...
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time....
Landmark Bancorp Inc: 1 director
A director at Landmark Bancorp Inc sold 12,992 shares at 25.085USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 491,000 shares of the Company's common stock in connec...
Landmark Bancorp, Inc. Announces 6.3% Increase in Net Earnings for the...
Landmark Bancorp, Inc. Announces 6.3% Increase in Net Earnings for the Year Ended December 31, 2024, and Fourth Quarter Earnings Per Share of $0.57. Declares Cash Dividend of $0.21 per Share Manhattan, KS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.57 for the three months ended December 31, 2024, compared to $0.68 per share in the third quarter of 2024 and $0.46 per share in the same quarter last year. Net income for the fourth quarter totaled $3.3 million, compared to $2.6 million in the fourth quarter of ...
Calavo Growers, Inc. Board of Directors Elects New Chair
Calavo Growers, Inc. Board of Directors Elects New Chair Outgoing Chair to Remain as Director SANTA PAULA, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today announced that its Board of Directors has elected Farha Aslam as its Chair effective immediately. “I am honored to serve as Chair of Calavo Growers, and I appreciate the opportunity to play an integral role in this 100-year-old company,” Ms. Aslam said. “Calavo has a heritage of leadership in the avocado industry, and today it is capitalizing...
Calavo Growers, Inc. Announces Fourth Quarter and Fiscal Year 2024 Fin...
Calavo Growers, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results SANTA PAULA, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today reported its financial results for the fiscal fourth quarter and fiscal year ended October 31, 2024. Introductory Note: In the first quarter of 2024, we concluded that the Fresh Cut (formerly RFG) business met the requirements to be classified as held for sale and discontinued operations. As a result, the financial results of that business are reported ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with their emplo...
Calavo Growers Declares Quarterly Dividend
Calavo Growers Declares Quarterly Dividend SANTA PAULA, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in the processing and distribution of avocados, tomatoes, papayas, and guacamole, today announced that its Board of Directors declared a quarterly cash dividend on its common stock of $0.20 per share. The dividend is to be paid on January 31, 2025, to shareholders of record as of the close of business on January 10, 2025. About Calavo Growers, Inc.Calavo Growers, Inc. (Nasdaq: CVGW) is a global leader in the processing and distribution of avocados, tomatoe...
Calavo Growers Announces Release Date for Fourth Quarter and Full-Year...
Calavo Growers Announces Release Date for Fourth Quarter and Full-Year 2024 Financial Results SANTA PAULA, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in the processing and distribution of avocados, tomatoes, papayas, and guacamole, today announced that it plans to release financial results for the fiscal fourth quarter and fiscal year ended October 31, 2024 and file its Form 10-K for the 2024 fiscal year after the market closes on Tuesday, January 14, 2025. As an “accelerated filer,” the Company is allowed up to 75 days following its fiscal year-end to ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 2, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 152,000 shares of the Company's common stock in connection with their empl...
Calavo Growers, Inc. Announces CFO Change in Leadership
Calavo Growers, Inc. Announces CFO Change in Leadership James Snyder to become Chief Financial Officer as Shawn Munsell Departs for New Role SANTA PAULA, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in the processing and distribution of avocados, tomatoes, papayas, and guacamole, today announced that James Snyder will become the Company’s new Chief Financial Officer effective December 2. Shawn Munsell, Calavo’s current CFO will be departing the Company on November 29 to pursue a new opportunity. He will serve as a consultant to the Company in the month o...
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and...
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4) Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development p...
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results ...
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2024, and host a corporate update conference call and webcast on Wednesday, November 13, 2024, at 4:30 PM East...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connec...
Landmark Bancorp, Inc. Announces 30.5% Increase in Third Quarter Net E...
Landmark Bancorp, Inc. Announces 30.5% Increase in Third Quarter Net Earnings and Earnings Per Share of $0.72. Declares Cash Dividend of $0.21 per Share and 5% Stock Dividend Manhattan, KS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.72 for the three months ended September 30, 2024, compared to $0.55 per share in the second quarter of 2024 and $0.52 per share in the same quarter last year. Net earnings for the third quarter of 2024 amounted to $3.9 million, compared to $3.0 million in the prior quarter and $...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.